Zobrazeno 1 - 10
of 29
pro vyhledávání: '"C Palomo-Palomo"'
Autor:
D Guerra Estévez, M Romero Alonso, C Palomo Palomo, M Reyes Malia, E Contreras Macías, A Ganfornina Andrades, J Estaire Gutiérrez
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
D Guerra Estévez, M Reyes Malia, C Palomo Palomo, M Romero Alonso, E Contreras Macías, A Ganfornina Andrades, J Estaire Gutiérrez
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
C Palomo-Palomo, D Guerra Estevez, MM Romero Alonso, A Parrado Gonzalez, M Reyes Malia, J Estaire Gutierrez
Publikováno v:
Section 4: Clinical pharmacy services.
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Dupilumab is authorised in the European Union for the treatment of moderate to severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. It is a non-funded drug in Spain, so patients can only
Autor:
Mdp Briceño-Casado, JM Borrero-Rubio, E Rios-Sanchez, Silvia Fénix-Caballero, MJ Gandara-LadronDeGuevara, J Diaz-Navarro, Gil-Sierra, FJ Salmeron-Navas, EJ Alegre-Del Rey, C Palomo-Palomo, C Martinez-Diaz
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background In clinical practice, dimethylfumarate is considered an alternative at the level of conventional systemic drugs in the first line (cyclosporine, methotrexate, acitretin) for moderate-to-severe plaque psoriasis (PP). Purpose To establish wh
Autor:
Mdp Briceño-Casado, Gil-Sierra, EJ Alegre-Del Rey, JF Lopez-Vallejo, C Palomo-Palomo, JM Borrero-Rubio, E Rios-Sanchez, C Martinez-Diaz, F Tellez-Perez, J Diaz-Navarro, Silvia Fénix-Caballero
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background To eliminate hepatitis C virus (HCV) infection in institutionalised patients it is necessary to reduce the risk of transmission in the general population. There is a high prevalence of HCV infection in the prison population (PP). Purpose T
Autor:
Gil-Sierra, JM Borrero-Rubio, E Rios-Sanchez, C Martinez-Diaz, EJ Alegre-Del Rey, C Palomo-Palomo, Mdp Briceño-Casado, M Camean-Castillo, J Diaz-Navarro, F Tellez-Perez, Silvia Fénix-Caballero
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background The European Medicines Agency authorised glecaprevir/pibrentasvir combination for treatment of hepatitis C virus (HCV) infection in July 2017. Treating hospital patients and the institutionalised population is essential in reducing transmi
Autor:
EJ Alegre-Del Rey, C Palomo-Palomo, Mdp Briceño-Casado, Gil-Sierra, FJ Salmeron-Navas, JM Borrero-Rubio, E Rios-Sanchez, C Martinez-Diaz, M Camean-Castillo, J Diaz-Navarro
Publikováno v:
Eur J Hosp Pharm
Background Biologic drugs have demonstrated efficacy and safety in the treatment of psoriasis. Frequently, label doses tend to be reduced in clinical practice when a sustained response has been reached. Purpose To assess the proposals of a committee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16f55726347685de3d4800e7859dcf9
https://europepmc.org/articles/PMC7535386/
https://europepmc.org/articles/PMC7535386/
Autor:
Mdp Briceño-Casado, Gil-Sierra, JM Borrero-Rubio, E Rios-Sanchez, M Camean-Castillo, JF Lopez-Vallejo, J Diaz-Navarro, EJ Alegre-Del Rey, C Palomo-Palomo, JC Garciadeparedes-Esteban, C Martinez-Diaz
Publikováno v:
Eur J Hosp Pharm
Background Aflibercept is indicated for adults in the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME) or myopic
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.